Stoke Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $184.4M | $36.6M | $8.8M | $12.4M | — |
| Operating income | -$20.6M | -$101.4M | -$114.8M | -$104.4M | -$86.1M |
| Operating expenses | $205.0M | $137.9M | $123.6M | $116.8M | $86.1M |
| Cash from operations | $45.6M | -$86.9M | -$81.1M | -$31.9M | -$66.9M |
| Capital expenditure | $670,000 | $203,000 | $1.6M | $4.0M | $1.2M |
| Free cash flow | $44.9M | -$87.1M | -$82.7M | -$35.8M | -$68.1M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $418.4M | $271.6M | $228.3M | $256.1M | $238.9M |
| Total liabilities | $66.0M | $42.5M | $68.8M | $71.2M | $21.1M |
Shares outstanding 62.3M · Free float 90.5%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.